DALLAS, June 12, 2019 (GLOBE NEWSWIRE) -- via OTC
PR WIRE -- Puration, Inc. (PURA) (“PURAâ€)
today announced signing a new West Coast Distributor for its EVERx
CBD Sports Water. The distributor is headquartered in Oregon. PURA
currently has over $1 million in annualized
revenue primarily from the sales of its EVERx CBD Sports
Water. Sales of EVERx today come primarily from the South and South
West United States. PURA recently announced signing a new East
Coast Distributor as well. PURA has announced a 2019 $4
million revenue target.
PURA Speculative Buy Recommendation and
$0.25 PPS Target w/Potential to $0.35
Goldman Small Cap Research has released a new
research report recommending PURA as a Speculative BUY with a
$0.25 PPS Target. Goldman Small Cap Research further
reports that the shares of PURA “have the potential to reach the
$0.35 mark.†The report highlights PURA’s growing EVERx CBD
Sports Water sales and the coming introduction of new beverages as
well as the potential for the company to exceed its 2019 sales
targets through the pending doubling of its production capacity and
through planned acquisitions. The report further details recent
updates intended to accelerate the issue of Nouveau (NOUV) stock to PURA shareholders in a dividend
distribution. Notably, the report points to the capacity and
quality improvements enabled by the addition of a new team member
with exceptional beverage industry professional experience.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Contact:
Puration, Inc.
Brian Shibley,
[email protected]
(800) 861-1350